Back

Corrigendum to: Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease

Cardiovascular Research

16 November 2020
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Effectiveness and safety of rivaroxaban vs apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease
30 August 2025
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial
30 August 2020
thumbnail
Congress Presentation
Perioperative management of antithrombotic therapy.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources